Share This Article:

Neuroblastoma in Saudi Children: A Single Center Experience (2006-2014)

Abstract Full-Text HTML XML Download Download as PDF (Size:361KB) PP. 896-905
DOI: 10.4236/jct.2015.610098    2,693 Downloads   3,091 Views   Citations

ABSTRACT

Introduction: Neuroblastoma is the most common extracranial solid tumor in childhood and survival rate has improved during the last few decades. Only a few studies, related to Neuroblastoma in Saudi Arabian children, have been performed. We report epidemiologic data and our clinical experience from the department of Pediatric Hematology Oncology (PHO), King Fahad Medical City (KFMC), Riyadh, Saudi Arabia. Method: A retrospective observational study of all patients, with diagnosis of Neuroblastoma, who attended PHO-KFMC from July 2006 to June 2014 was performed. The survival periods (overall survival and disease-free survival) and the final outcomes for patients treated and followed at KFMC were recorded. The survival data were statistically correlated with the clinical, pathological and biological features of patients and tumors and compared to national and international cohorts. Results: Eight-year data were available for the 42 patients of which 22 (52.4%) were male and 20 (47.6%) were females. Age at diagnosis ranged 0 - 91 months with a mean and median of 26.3 and 18.5 months respectively. 16 (38.1%) patients were under one year and 26 (61.9%) above 1 year of age. The event-free survival (EFS) and overall survival (OS) rates were 66.5% and 71.5% respectively. EFS and OS among those who were <1 year age at presentation was 75% and 82%, whereas ≥1 yr age group had 59% and 62% survival rates respectively. Patients with tumors in the adrenal had considerably lower EFS (59%) and OS (63%); in comparison to patients with tumors sites other than the adrenal who had EFS and OS of 85% and 89% respectively. Both EFS and OS survival rates at the end of follow-up interval were 100.0%, in the low and intermediate risk groups. In contrast, patients in the high risk group had EFS and OS rates of 44% and 48% respectively. This difference was statistically significant (p < 0.05). Conclusion: Our results are very encouraging and comparable with known published international cohorts, and reveal an excellent outcome for stage 1, 2, 3 & 4 s. The prognosis for advanced (stage 4) disease remains rather poor. A collaborative Saudi-wide effort, with an emphasis on research in detecting clinical and biologic characteristics of aggressive disease and tailoring therapy, is needed.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Naqib, Z. , Ahmed, A. , Harbi, M. , Manjomi, F. , Khan, Z. , Alanazi, A. , Mosleh, O. , Ballourah, W. and Rayis, M. (2015) Neuroblastoma in Saudi Children: A Single Center Experience (2006-2014). Journal of Cancer Therapy, 6, 896-905. doi: 10.4236/jct.2015.610098.

References

[1] Brodeur, G.M. and Marris, J.M. (2006) Neuroblastoma. In: Pizzo and Poplack, B.G., Eds., Principles and Practice of Pediatric Oncology, 5th Edition, Lippincott Williams & Wilkins, Philadelphia, 933-970.
[2] Matthay, K.K., Villablanca, J.G., Seeger, R.C., Stram, D.O., Harris, R.E., Ramsay, N.K., et al. (1999) Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-Cisretinoic Acid. New England Journal of Medicine, 341, 1165-1173.
http://dx.doi.org/10.1056/NEJM199910143411601
[3] Brodeur, G.M. (2003) Neuroblastoma: Biological Insights into a Clinical Enigma. Nature Reviews Cancer, 3, 203-216.
http://dx.doi.org/10.1038/nrc1014
[4] Maris, J.M. and Matthay, K.K. (1999) Molecular Biology of Neuroblastoma. Journal of Clinical Oncology, 17, 2264-2279.
[5] Gustafson, W.C. and Matthay, K.K. (2011) Progress towards Personalized Therapeutics: Biologic- and Risk-Directed Therapy for Neuroblastoma. Expert Review of Neurotherapeutics, 11, 1411-1423.
http://dx.doi.org/10.1586/ern.11.103
[6] Canete, A., Gerrard, M., Rubie, H., et al. (2009) Poor Survival for Infants with MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. Journal of Clinical Oncology, 27, 1014-1019.
http://dx.doi.org/10.1200/JCO.2007.14.5839
[7] Kerbl, R., Urban, C.E., Ambros, I.M., et al. (2003) Neuroblastoma Mass Screening in Infancy: Insights into the Biology of Neuroblastic Tumors. Journal of Clinical Oncology, 21, 4228-4234.
http://dx.doi.org/10.1200/JCO.2003.10.168
[8] Schilling, F.H., Spix, C., Berthold, F., et al. (2002) Neuroblastoma Screening at One Year of Age. New England Journal of Medicine, 346, 1047-1053.
[9] Woods, W.G., Gao, R.N., Shuster, J.J., et al. (2002) Screening of Infants and Mortality Due to Neuroblastoma. New England Journal of Medicine, 346, 1041-1046.
http://dx.doi.org/10.1056/NEJMoa012387
[10] Al-Mulhim, I. (1998) Neuroblastoma in Children: A 10-Year Experience in Saudi Arabia. Journal of Tropical Pediatrics, 44, 77-80.
http://dx.doi.org/10.1093/tropej/44.2.77
[11] Fayea, N.Y., Atra, A.A., Khattab, T., Elimam, N.A., Felimban, S., Yousef, A., Basheer, A., Zayed, A., Baothman, A., Al-Sheikh, N. and Hussen, W. (2008) Outcome of Children Older than One Year with Neuroblastoma. Neurosciences (Riyadh), 13, 49-52.
[12] Elimam, N.A., Atra, A.A., Fayea, N.Y., Al-Asaad, T.G., Khattab, T.M., Al-Sulami, G.A. and Felimban, S.K. (2006) Stage 4S Neuroblastoma, a Disseminated Tumor with Excellent Outcome. Saudi Medical Journal, 27, 1734-1736.
[13] Papaioannou, G. and McHugh, K. (2005) Neuroblastoma in Childhood: Review and Radiological Findings. Cancer Imaging, 5, 116-127.
http://dx.doi.org/10.1102/1470-7330.2005.0104
[14] Smith, M.A., Seibel, N.L., Altekruse, S.F., et al. (2010) Outcomes for Children and Adolescents with Cancer: Challenges for the Twenty-First Century. Journal of Clinical Oncology, 28, 2625-2634.
http://dx.doi.org/10.1200/JCO.2009.27.0421
[15] Horner, M.J., Ries, L.A., Krapcho, M., et al. (2009) SEER Cancer Statistics Review, 1975-2006. National Cancer Institute, Bethesda.
[16] Nuchtern, J.G., London, W.B., Barnewolt, C.E., et al. (2012) A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants: A Children’s Oncology Group Study. Annals of Surgery, 256, 573-580.
http://dx.doi.org/10.1097/SLA.0b013e31826cbbbd
[17] Joshi, V.V., Cantor, A.B., Brodeur, G.M., et al. (1993) Correlation between Morphologic and Other Prognostic Markers of Neuroblastoma: A Study of Histologic Grade, DNA Index, N-Myc Gene Copy Number, and Lactic Dehydrogenase in Patients in the Pediatric Oncology Group. Cancer, 71, 3173-3181.
http://dx.doi.org/10.1002/1097-0142(19930515)71:10<3173::AID-CNCR2820711045>3.0.CO;2-P
[18] Vo, K.T., Matthay, K.K., Neuhaus, J., London, W.B., Hero, B., Ambros, P.F., Nakagawara, A., Miniati, D., Wheeler, K., Pearson, A.D.J., Cohn, S.L. and DuBois, S.G. (2014) Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project. JCO, 56, 1621.
[19] Shuster, J.J., McWilliams, N.B., Castleberry, R., et al. (1992) Serum Lactate Dehydrogenase in Childhood Neuroblastoma: A Pediatric Oncology Group Recursive Partitioning Study. American Journal of Clinical Oncology, 15, 295-303.
http://dx.doi.org/10.1097/00000421-199208000-00004
[20] Minard, V., Hartmann, O., Peyroulet, M.C., Michon, J., Coze, C., Defachelle, A.S., Lejars, O., Perel, Y., Bergeron, C., Boutard, P., Leverger, G., Stephan, J.L., Thyss, A., Chastagner, P., Couillault, G., Devalck, C., Lutz, P., Mechinaud, F., Millot, F., Plantaz, D., Rialland, X. and Rubie, H. (2000) Adverse Outcome of Infants with Metastatic Neuroblastoma, MYCN Amplification and/or Bone Lesions: Results of the French Society of Pediatric Oncology. British Journal of Cancer, 83, 973-979.
http://dx.doi.org/10.1054/bjoc.2000.1412

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.